


PRODUCT INFORMATION

2-(1-(3-(2,4-Dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic Acid

Item No. 45721

CAS Registry No.: 2654826-81-8
Formal Name: 1-[5-fluoro-1-methyl-3-(tetrahydro-2,4-dioxo-1(2H)-pyrimidinyl)-1H-indazol-6-yl]-4-hydroxy-4-piperidineacetic acid

MF: C₁₉H₂₂FN₅O₅
FW: 419.4
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

2-(1-(3-(2,4-Dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid is supplied as a crystalline solid. A stock solution may be made by dissolving the 2-(1-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid in the solvent of choice, which should be purged with an inert gas. 2-(1-(3-(2,4-Dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid is sparingly soluble (1-10 mg/ml) in DMSO.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of 2-(1-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid can be prepared by directly dissolving the crystalline solid in aqueous buffers. 2-(1-(3-(2,4-Dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid is slightly soluble (0.1-1 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

2-(1-(3-(2,4-Dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid is a proteolysis-targeting chimera (PROTAC) building block.¹ It has been used in the synthesis of a PROTAC that drives mutant B-RAF degradation.

Reference

1. Jackson, K.L., Liang, Y., Hanley, R.P., *et al.* Compounds for the degradation of mutant BRAF. *C4 Therapeutics, Inc. WO2025/096858A1* (2025).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/26/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM